RxDoctor Payments Data

Nancy Kaddis, MD

Internal Medicine · Cambridge, MANPI 1053554949

Payments from drug & device makers

$11,908in general payments, 2019–2025

Across 31 payments — averaging $384.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$5K
  • AbbVie$3K
  • Genmab U.S., Inc.$2K
  • Epizyme, Inc.$721
  • AstraZeneca$568
  • Gilead$338
  • plus $188 from 2 others

What the payments were for

  • Consulting fees$9,04776%
  • Speaking & faculty fees$6005%
  • Travel & lodging$6626%
  • Food & beverage$1,35711%
  • Education$2412%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi5$5,065
AbbVie10$2,892
Genmab U.S., Inc.7$2,136
Epizyme, Inc.2$721
AstraZeneca2$568
Gilead3$338
Johnson & Johnson1$95
Incyte Corporation1$92

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,908 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$130,178
Medicare patients
518
Services billed
1,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide92$1,529,583
PomalystPomalidomide57$1,280,299
Lenalidomide54$779,640
JaypircaPirtobrutinib24$533,344
BrukinsaZanubrutinib31$352,979
XtandiEnzalutamide21$296,562
VenclextaVenetoclax29$272,539
IclusigPonatinib Hcl11$238,759
CalquenceAcalabrutinib Maleate13$201,742
ImbruvicaIbrutinib16$197,381
IbrancePalbociclib11$173,730
EliquisApixaban81$84,276
XareltoRivaroxaban26$35,045
Imatinib Mesylate11$31,399
OxycontinOxycodone Hcl18$7,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$2,892$272,53929 claims
AstraZenecaCalquence$568$201,74213 claims
Johnson & JohnsonXarelto$95$35,04526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →